Fundraising FoxAchelios Therapeutics
Chapel Hill, US · Founded 2012 · Delaware corporation
Find your way into Achelios Therapeutics
Sign up to see every warm intro you have to Achelios Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Achelios Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Achelios Therapeutics develops therapies for chronic pain conditions including temporomandibular joint pain, migraine, and arthritis-related joint pain through repurposed and reformulated drug candidates. The company addresses unmet medical needs in chronic pain that have been underserved by larger pharmaceutical firms.
Founders & leadership
CJ
Crist J. FrangakisPresident & CEOCrist J. Frangakis is an executive officer and director at Achelios Therapeutics. He brings experience in pharmaceutical R&D licensing and business development, with background in cardiovascular and endocrine therapeutics.
Board
RV
Ron VeredBoard director
JR
Jerry RosenblattBoard director
WD
William DickieBoard director
WB
William BauerBoard director
Reported raises · per SEC filings
Form D private placements$3.5M disclosed across 2 rounds · 2012–2016
▶$350KraisedApr 2016 · 2 investors · Other Health CareRule 506(b)
▶$350KraisedApr 2016 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ron VeredDirector
- Crist J. FrangakisExecutive Officer, Director
- Jerry RosenblattDirector
- Offering amount
- $2M
- Amount sold
- $350K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$3.2MraisedMar 2014 · 33 investors · PharmaceuticalsRule 506(b)
▶$3.2MraisedMar 2014 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Crist J. FrangakisExecutive Officer, Director
- Ron VeredDirector
- William DickieDirector
- William BauerDirector
- Offering amount
- $4.3M
- Amount sold
- $3.2M
- Minimum investment
- $10K
- Proceeds to insiders
- $700K
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 9
ElicioElicio Therapeutics is a biopharmaceutical company focused on developing therapeutic treatments.
Xilio TherapeuticsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
LexeotxLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.
AlloyAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Aulos BioscienceAulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.
CalliotxCallio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
Seelos TherapeuticsSeelos Therapeutics is a biopharmaceutical company based in New York. The page provides corporate and legal details but limited information about its specific therapeutic focus.
Aligos TherapeuticsAligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
Alexion PharmaceuticalsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Companies working in the same space as Achelios Therapeutics.
Frequently asked questions
- What does Achelios Therapeutics do?
- Achelios Therapeutics develops therapies for chronic pain conditions including temporomandibular joint pain, migraine, and arthritis-related joint pain through repurposed and reformulated drug candidates. The company addresses unmet medical needs in chronic pain that have been underserved by larger pharmaceutical firms.
- How much funding has Achelios Therapeutics raised?
- Achelios Therapeutics has disclosed $3.5M raised across 2 rounds.
- Where is Achelios Therapeutics headquartered?
- Achelios Therapeutics is headquartered in Chapel Hill, US.